

## CLEMENT WEINBERGER, PhD

---

### July 2008 to Present

*Freelance editor and Founder/owner*, The Stylus: medical and scientific communications services to assist investigators prepare, submit, and revise publication manuscripts; publication planning; scientific and medical documentation, and bibliographic research. *website*: <http://www.stylusedits.com> *Blog*: <http://biocareers.com/bio-careers-blog?title=&tid=All&uid=Clement+Weinberger>, *LinkedIn*: <http://www.linkedin.com/pub/clement-weinberger/0/739/489>

### September 2002 to July 2008

*Director Medical Communications and Training*, *Medical Affairs International*, Sanofi Pasteur, Lyon, France: Responsible for publication strategies for Sanofi Pasteur vaccines, presentation and publication of completed studies, direct training on diseases and products for the SP international zone. Direct the activities of an e-Communications Manager, Medical Documentation Coordinator, Training Manager and an Assistant.

### June 1999 to September 2002

*Scientific Communications Director*, CPE Communications, Morristown, NJ: Primary responsibilities included development of publication strategies for a variety of pharmaceutical products in all stages of the product life cycle. I also worked with medical writers, investigators, and clients to publish the reports and reviews recommended in the publication plans.

### 1996 to June 1999

*Scientific/Medical Director*, Churchill Communications North America, Inc. Secaucus, NJ: Coordinated development and production of symposia, speakers bureaus, and scientific poster presentations, journal publication manuscripts, monographs, newsletters, teleconferences, publication plans, and other medical education programs.

### 1993 to 1996

*Technical Writer*, Health Science Communications, New York, NY: Writing for medical education projects including slide-lecture kits speaker bureau presentations, product monographs, and symposium-related publications.

*Lecturer*, Bergen Community College, Paramus, NJ: Taught biology, anatomy and human physiology courses in the Division of Natural Sciences and Mathematics. This was a full time non-tenure-track position.

### 1989 to 1993

*Oncology Services Specialist*, Molecular Oncology, Inc., (MOI), Gaithersburg MD: Sold reference-testing services to hospital pathologists and laboratories in Northern New Jersey and the Bronx and Westchester, New York. I introduced MOI to a highly competitive market and captured a significant market share selling against major, well-established laboratories, with over 30% of the 60 hospitals in my territory sending specimens for testing. I was the top salesperson of 1991. MOI was sold in the spring of 1993 and ceased operations.

### 1983 to 1989

*Product Marketing Manager*, Pall Biomedical Products Corporation, East Hills, NY: Developed the marketing strategy and launch of technologically innovative medical devices (leukocyte removal blood filters) for hospital and laboratory use. In addition, I developed product-related sales training and inservice programs, sales aids, bulletins and monographs. My first position at Pall was preparing and presenting "peer-to-peer" seminars to physicians, nurses, therapists, laboratory and clinical specialists.

### 1977 to 1983

- *Research Fellow*, Memorial Hospital Sloan-Kettering Cancer Center, NY, NY: Cell and tissue culture, production of monoclonal antibodies, immunohistochemistry, and tumor growth studies (concurrent with teaching post).
- *Assistant Professor*, Department of Biology, Seton Hall University, South Orange, NJ
- *Assistant Professor*, Department of Biology, William Paterson University, Wayne, NJ
- *Assistant Professor* (Adjunct), Department of Biology, New York University, NY, NY

### 1967 to 1977

- *Post-Doctoral Research Fellow*, Hubrecht Laboratory, Utrecht, Netherlands
- *Graduate Student/Teaching Assistant*, New York University, NY, NY
- *Science Teacher*, The Franklin School, NY, NY

### Education

PhD	Cell Biology	New York University, NY, USA 1976
MS	Cell Biology	New York University, NY, USA 1974
BS	Biology	Fairleigh Dickinson University, NJ, USA 1967

## Publications List

- Arnoux S, Weinberger C, Gessner BD. Vaccine-preventable influenza disease burden from clinical trials of Vaxigrip – an inactivated split virion influenza vaccine - supports wider vaccine use. *Vaccine* 2007;25(45):7720–31.
- Bonnet MC, Dutta A, Weinberger C, Plotkin SA. Mumps vaccine virus strains and aseptic meningitis. *Vaccine* 2006;24(49–50):7037–45.
- Brick, I., and Weinberger, C. (1984). Electrophoretic properties, cell surface morphology, and calcium in amphibian gastrulation. *Am. Zool.* 1984;24:629–647.
- Dutta AK, Weinberger C, Houillon G, Rassouli A, Worldwide experience with a purified vero-cell-culture rabies vaccine. *APCRI J* 2006;8. epub available from: <http://www.apcri.org/v8wrddwd.htm>
- Dutta A, Weinberger C, Bonnet M-C. *Haemophilus influenzae* type b conjugate vaccines: efficacy and safety. *Asian-Oceanian Journal of Pediatrics and Child Health* 2004;3(2):80–89.
- Helson L, Weinberger C, Helson C, Lieberman P. Neuroectodermal tumor and monoclonal antibodies. *Am J Pediatr Hematol Oncol.* 1984;6(3):227–31.
- Helson L, Helson C, Weinberger C. Immunoreactive prothrombin-like material in hepatoblastoma and other tumor monolayers. *Pediatric hematology and oncology* 1983;1(1):85–7.
- Primary hypoblast development in the chick I. Scanning electron microscopy of normal development. *Devel Genes Evol* 1982;191:119–126.
- Weinberger CP, Brick I. Locomotion and adhesion of amphibian gastrula and neurula cells cultured on substrata of varied surface charge. *Exp Cell Res* 1980;130(2):251–63.
- Weinberger C, Penner PL, Brick I. Polygression, an important morphogenetic movement in chick gastrulation. *Am. Zool* 1984;24(3):545–54.

## Publications with acknowledgement of writing assistance

### Vaccines/vaccine-related

- Abarca K, Ibáñez I, Perret C, Vial P, Zinsou JA. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children. *Int J Infect Dis* 2008;12(3):270–7.
- Aquino AG, Brito MG, Doniz CE, Herrera JF, Macias M, Zambrano B, Plennevaux E, Santos-Lima E. A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children *Vaccine.* 2012;
- Avila Aguero ML, Soriano-Fallas A, Umaña-Sauma MA, Ulloa-Gutierrez R, Arnoux S. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children. *Medicina (B Aires)* 2007;67(4):351–9.
- Bonnet MC, Dutta A. World wide experience with inactivated poliovirus vaccine. *Vaccine* 2008;26(39):4978–83.
- Capeding MR, Cadorna-Carlos J, Book-Montellano M, Ortiz E. Immunogenicity and safety of a DTaP-IPV//PRP–T combination vaccine given with hepatitis B vaccine: a randomized open-label trial. *Bull World Health Organ* 2008;86(6):443–51.
- Ceyhan M, Yildirim I, Kurt N, Uysal G, Dikici B, Ecevit C, Aydogan A, Koc A, et al. Differences in hepatitis A seroprevalence among geographical regions in Turkey: a need for regional vaccination recommendations. *J Viral Hepatitis* 2008; 15(Suppl. 2): 69–72.
- Dutta A. Epidemiology of poliomyelitis—options and update. *Vaccine.* 2008 Oct 23;26(45):5767–73.
- Dutta AK, Verghese VP, Pemde HK, Mathew LG, Ortiz E. Immunogenicity and safety of a pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, *Haemophilus influenzae* type b conjugate combination vaccine (Pentaxim™) at 6, 10, 14 weeks of age. *Indian Pediatrics* 2009;46:975–982. <http://indianpediatrics.net/index.htm>
- Espul C, Benedetti L, Cuello H, Houillon G, Rasuli A. Persistence of immunity from one year of age after one or two doses of hepatitis A vaccine given to children in Argentina. *Hepat Med* 2012;4:53–60.
- Frey S, Vesikari T, Szymczakiewicz- Multanowska A, Lattanzi M, Izu A, Groth N, Holmes S. Clinical efficacy of cell culture–derived and egg- derived inactivated subunit influenza vaccines in healthy adults. *Clin Infect Dis* 2010;51:000–000 <http://www.journals.uchicago.edu/doi/abs/10.1086/656578>

Gold R, Barreto L, Ferro S, Thippawong J, Guasparini R, Meekison W, et al. Safety and immunogenicity of a fully liquid vaccine containing five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-*Haemophilus influenzae* type b conjugate vaccines administered at 2, 4, 6 and 18 months of age. *Can J Infect Dis Med Microbiol* 2007;18(4):241–8.

Fisenka EG, Germanovich, FA Glinskaya IN, Lyabis OI, Rasuli AM. Effectiveness of universal hepatitis A immunization of children in Minsk City, Belarus: four-year follow-up. *J Viral Hepatitis* 2008;15(Suppl2): 57–61.

Kuanprasert S, Apichartpikul N, Chuenkitmongkol S, Wiangosot W, Topaiboon P, Sukonthasarn A. Evidence of influenza or influenza-like-illness preceding acute coronary syndrome. *Southeast Asian J Trop Med Public Health* 2008;39(6):1040–4.

Kmiecik T, Arnoux S, Kobryn A, Gorski P. Influenza vaccination in adults with asthma: safety of an inactivated trivalent influenza vaccine. *J Asthma*. 2007;44(10):817–22.

Lang J, Feroldi E, Vien NC. Pre-exposure purified vero cell rabies vaccine and concomitant routine childhood vaccinations: 5-year post-vaccination follow-up study of an infant cohort in Vietnam *J of Trop Pediatr* 2009;55(1):26–31.

Lee SY, Hwang HS, Kim JH, et al. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: A randomized, controlled study in infants in the Republic of Korea. *Vaccine*. 2011;29(8):1551–7.

Li RC, Li FX, Li YP, et al. Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated *Haemophilus Influenzae* type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China. *Vaccine* 2011 Feb 24;29(10):1913–20.

Li RC, Li YP, Yi N, et al. An open, prospective, randomized study comparing the immunogenicity and safety of two inactivated hepatitis A pediatric vaccines in toddlers, children and adolescents in China. *Pediatr Infect Dis J* 2012 (4 September, doi: 10.1097/INF.0b013e318271c4c3)

Madhi SA, Cutland C, Jones S, Groome M, Ortiz E. Immunogenicity and safety of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim™) and monovalent hepatitis B vaccine at 6, 10 and 14 weeks of age in infants in South Africa. *S Afr Med J* 2011;101:126–131.

Ripoll C, Ponce A, Wilson MM, Sharif N, Vides JB, Armoni J, Teuwen DE. Evaluation of two yellow fever vaccines for routine immunization programs in Argentina. *Hum Vaccin* 2008;4(2):121–6.

Thisyakorn U, Pancharoen C, Chuenkitmongkol S, Ortiz E. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim™) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine. *Southeast Asian J Trop Med Public Health* 2009;40(2):282–94.

Thisyakorn U, Chotpitayasonndh T, Pancharoen C, Chuenkitmongkol S, Ortiz E. Evaluation of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, HIBconjugate combined vaccine (Pentaxim™) at 2, 4, and 6 months of age plus hepatitis B vaccine at birth, 2, and 6 months of age in infants in Thailand. *Southeast Asian J Trop Med Public Health* 2010;41(2):250–262.

Vesikari T, Karvonen A, Tilman S, Borkowski A, Montomoli E, Banzhoff A, Clemens R. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. *Pediatrics*. 2010;126(4):e762–70.

Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L. Prevention of pneumococcal diseases in the post-seven valent vaccine era: A European perspective. *BMC Infect Dis* 2012, 12:207.

Yurdakök K, Bakir M, İnce T, et al. Immunogenicity and safety of an inactivated hepatitis Avaccine given with measles-mumps-rubella vaccine to 12–13-month-old Turkish Children. *J Vaccines Vaccin* 2012; 3:146.

## **Infectious diseases**

Adelglass J, Bundy JM, Woods R. Efficacy and tolerability of cefprozil versus amoxicillin/clavulanate for the treatment of adults with severe sinusitis. *Clin Ther* 1998;20(6):1115–29.

Dardick K. Educating travelers about malaria: dealing with resistance and patient noncompliance. *Cleve Clin J Med* 2002;69(6):469–79.

Elewski BE, Leyden J, Rinaldi MG, Atillasoy E. Office practice-based confirmation of onychomycosis: a US nationwide prospective survey. *Arch Intern Med* 2002;162(18):2133–8.

Garrelts JC, Wagner DJ. The pharmacokinetics, safety, and tolerance of cefepime administered as an intravenous bolus or as a rapid infusion. *Ann Pharmacother* 1999;33(12):1258–61. DOI 10.1345/aph.19067

Moyle G. Use of HIV protease inhibitors as pharmacoenhancers. *AIDS Read* 2001;11(2):87–98.

## **Diabetes**

Haller H. Postprandial glucose and vascular disease. *Diabetic Med* 1997;14(S3):S50–S56,

Liebl A. Challenges in optimal metabolic control of diabetes. *Diabetes Metab Res Rev* 2002;18(Suppl 3):S36–41.

Yki-Järvinen H. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus. *Diabetes Metab Res Rev* 2002;18(Suppl 3):S77–81.

### **Obesity**

Dujovne CA, Zavoral JH, Rowe E, Mendel CM; Sibutramine Study Group. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. *Am Heart J* 2001;142(3):489–97.

Fernstrom MH. Treating obesity in the family practice setting. *Postgrad Med* 2001;109(6 Suppl):10–8.

Glazer G. Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. *Arch Intern Med* 2001;13–27;161(15):1814–24.

Hauner H. Current pharmacological approaches to the treatment of obesity. *Int J Obes Relat Metab Disord* 2001;25(Suppl1):S102–6.

Phelan S, Wadden TA. Combining behavioral and pharmacological treatments for obesity. *Obes Res* 2002;10(6):560–74.

Wadden TA. Exploring synergies in the treatment of obesity. *Postgrad Med*. 2001;109(6 Suppl):29–33.

Wolf AM. The economic impact of obesity. Building bridges with managed care. *Postgrad Med*.2001;109(6 Suppl):34–9.

### **Oncology**

Chlebowski RT. Factors influencing the role of bisphosphonates in breast cancer management. *Semin Oncol* 2001;28(4 Suppl 11):42–8.

Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. *Clin Cancer Res* 2000;6(7):2585–97.

Slack JL, Samuel Waxman S, Guido Tricot G, et al. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies. *The Oncologist* 2002;7(Suppl 1):1–13.

Syrigos KN, Pliarchopoulou K, Harrington KJ. The development of monoclonal antibody therapy in leukemias. *Hybridoma* 2001;20(3):145–8.

Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. *Br J Cancer* 2000;83(5):588–93

### **Hematopoietic growth factors**

Brandberg Y. Assessing the impact of cancer-related anaemia on quality of life and the role of rHuEPO. *Med Oncol* 2000;17(Suppl 1):S23–31.

Coiffier B. The impact and management of anaemia in haematological malignancies. *Med Oncol* 2000;17(Suppl 1):S2–10.

Da Costa RM, Ribeiro Jesus FM, Aniceto C, Mendes M. Granulocyte-macrophage stimulating factor in patients with chronic venous leg ulcers. *Wound Repair Regen* 1999;7(1):17–25.

Erslev AJ. Erythropoietin and anemia of cancer. *Eur J Haematol* 2000;64(6):353–8.

### **Epilepsy**

Bebin EM. Additional modalities for treating acute seizures in children: overview. *J Child Neurol* 1998;13(Suppl 1):S23–6

Pellock JM Use of midazolam for refractory status epilepticus in pediatric patients. *J Child Neurol* 1998;13(12):581–7.

Towne AR, DeLorenzo RJ. Use of intramuscular midazolam for status epilepticus. *J Emerg Med* 1999;17(2):323–8.